

DISEASES & POPULATIONS WE TARGET

Our programs are working on **OVER 90 DIFFERENT DISEASES** and our programs are tailored to the **SPECIFIC HEALTH CHALLENGES** effecting the communities we are working in. We support a **RANGE OF DIFFERENT POPULATION GROUPS** depending on local health challenges.

Over **90**

different diseases

DISEASES

THE TOP 5 DISEASES WE ARE WORKING ON ARE:




POPULATION

THE TOP 5 POPULATIONS WE ARE SUPPORTING ARE:



HOW WE SUPPORT THESE POPULATIONS



OUR HOLISTIC PROGRAM APPROACHES

Our collaborations help to **INCREASE CARE AND ACCESS TO DIAGNOSIS, TREATMENT AND VACCINES** for more people across the world.

We use a diversity of holistic approaches, from R&D to community awareness and health promotion and embed gains in local healthcare systems to help local governments meet community needs and build long-term capacity.

OUR RANGE OF PROGRAM STRATEGIES AND APPROACHES INCLUDES:

Prevention strategies
71 Programs

Strengthening health systems
67 Programs

Increasing community awareness and linking to care
96 Programs

Health service delivery
121 Programs

Drug development and research
64 Programs

OUR GLOBAL REACH


We are working on **OVER 250 CROSS-SECTOR COLLABORATIONS** across the globe, almost half of these are in Africa and **OVER 60 PROGRAMS ARE GLOBAL COMMITMENTS.**

More than **250**
cross-sector collaborations

Over **60**

programs are global commitments

We are working in **EVERY REGION AROUND THE GLOBE**



The **TOP 5 COUNTRIES** we work in are...

OUR DIVERSE PARTNERS

IFPMA members collaborate...

with over **1200**

cross-sector partners to develop extensive global health programs

on over **35**


programs to collectively drive progress towards the global goals

more than **130**

programs include collaborations with more than one partner type

PARTNER TYPES

WE WORK WITH A DIVERSITY OF PARTNERS:



COMMON PARTNERS

THE MOST COMMON PARTNERS WE WORK WITH ARE:

USAID
US Agency for International Development (USAID)
17 Programs

BILL & MELINDA GATES FOUNDATION
Bill and Melinda Gates Foundation
25 Programs

World Health Organization (WHO)
World Health Organization (WHO)
20 Programs

DNDi
Drugs for Neglected Diseases initiative (DNDi)
12 Programs

CLINTON HEALTH ACCESS INITIATIVE
Clinton Health Access Initiative
12 Programs

PRIVATE SECTOR

WE ARE WORKING WITH OVER

490

OTHER PRIVATE SECTOR PARTNERS INCLUDING:

→ Private foundation or development organization
78 PROGRAMS

→ Professional and trade associations
45 PROGRAMS

→ Generic manufacturers
35 PROGRAMS

→ Logistics and supply chain
15 PROGRAMS

PRIVATE SECTOR PARTNERS

THE MAIN PRIVATE SECTOR PARTNERS WE COLLABORATE WITH ARE:

ViiV Healthcare
ViiV Healthcare
6 Programs

Mylan
Mylan
5 Programs

Aspen
Aspen Pharmacare
5 Programs

BD
Becton Dickinson (BD)
3 Programs

Medicines Patent Pool
Medicines Patent Pool
5 Programs

axios
Axios International
3 Programs

THE COUNT DOWN TO THE SDGS

2020 MARKS THE 10-YEAR COUNT DOWN TO THE SUSTAINABLE DEVELOPMENT GOALS (SDGS).

The world depends on improved global health to continue to promote prosperity and enable human progress. Meeting the ambitious goals by 2030 will require further scientific breakthroughs and strategic innovations. The innovative biopharmaceutical industry recognizes that to achieve these goals and address current and future global health challenges, new and innovative collaborations are needed.

Our industry discovers, develops and delivers innovative medicines and vaccines that enable patients to live longer, healthier and more productive lives. In addition to our contribution to innovation, we develop holistic programs and use a range of strategies to support better health for all and progress toward achieving SDG3 and other related goals.



Ensuring healthy lives and promoting wellbeing for all at all ages – is core to everything we do.

OUR PROGRAMS ALSO SUPPORT THE SDG'S BEYOND HEALTH:



34%

of our programs support **SDG 5** (gender equality and women's empowerment)



40%

of our programs support **SDG 9** (build resilient infrastructure)



41%

of our programs support **SDG 10** (reduce inequalities)

OUR INNOVATIVE COLLABORATION APPROACHES

Our innovative partnerships are continually learning from each other, and through our **deep and trusted collaborations** we share insights and best practices from our experiences.

CHECK OUT OUR OTHER PUBLICATIONS WHICH CAPTURE OUR SPECIFIC CONTRIBUTIONS IN NTDs, HIV, TB AND MALARIA, AND UNIVERSAL HEALTH COVERAGE



Collaborating to end Neglected Tropical Diseases: Catalyzing Innovation and Partnerships



Stepping up the fight: Industry Collaboration to End HIV, Tuberculosis and Malaria



Achieving a Healthier and Sustainable Future for all: Policy Perspectives on Universal Health Coverage from the Innovative Biopharmaceutical Industry



Collaborating for a sustainable future

HEALTH FOR ALL

OUR COLLABORATIONS SUPPORTING THE SDGS



EXPLORE THE FULL RANGE OF OUR COLLABORATIONS ON **GLOBAL HEALTH PROGRESS** AND SEE HOW WE ARE ADDRESSING SOME OF THE MOST COMPLEX HEALTH CHALLENGES.

CHECK OUT: ifpma.org | globalhealthprogress.org

[@IFPMA](https://twitter.com/IFPMA) [@GlobalHealth](https://twitter.com/GlobalHealth)